Discover
ALVR
AlloVir, Inc.
9.81
undefined x undefined
undefined x undefined
bid
ask
+
0.39
4.14%
04:00 PM
| Ytd | ||
| 1y |
9.55
day range
10.32
52 week range
| Open | 9.55 | Prev Close | 9.42 | Low | 9.55 | High | 10.32 | Mkt Cap | N/A |
| Vol | 9.40K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -1.48 |
| Beta | 0.74 | Short Ratio | 20.03 | Inst. Own | 41.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 1.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.14 | -0.04 | 0.1 | 71.43% |
| 2024-08-09 | 2024-06 | -0.1 | -0.05 | 0.05 | 50.00% |
| 2024-05-13 | 2024-03 | -0.16 | -0.18 | -0.02 | -12.50% |
| 2024-03-15 | 2023-12 | -0.43 | -0.53 | -0.1 | -23.26% |
| 2023-11-02 | 2023-09 | -0.42 | -0.39 | 0.03 | 7.14% |
| 2023-08-03 | 2023-06 | -0.45 | -0.48 | -0.03 | -6.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-12-26 | B of A Securities | Downgrade | Buy | Underperform |
| 2023-12-22 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2023-12-22 | Piper Sandler | Downgrade | Overweight | Neutral |
| 2023-12-22 | JP Morgan | Downgrade | Overweight | Underweight |
| 2023-08-18 | B of A Securities | Upgrade | Buy | |
| 2023-08-07 | Morgan Stanley | Upgrade | Overweight | Overweight |
Profile
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-05 | BORNSTEIN JEFFREY S | Director | 110.20K | Stock Award(Grant) |
| 2024-11-18 | BRAINARD DIANA | Chief Executive Officer | 723.36K | Sale |
| 2024-06-05 | BRENNER MALCOLM | Director | 263.93K | Stock Award(Grant) |
| 2024-11-18 | HAGEN BRETT R. | Officer | 68.51K | Sale |
| 2024-06-05 | HALLAL DAVID L | Director and Beneficial Owner of more than 10% of a Class of Security | 19.68M | Stock Award(Grant) |
| 2024-06-05 | JOVAN-EMBIRICOS MORANA | Director and Beneficial Owner of more than 10% of a Class of Security | 26.60M | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | EcoR1 Capital, LLC | 11.29M | 5.36M | 9.77% |
| 2024-09-29 | Octagon Capital Advisors LP | 11.20M | 5.31M | 9.69% |
| 2024-09-29 | Siren, L.L.C. | 6.60M | 3.13M | 5.71% |
| 2024-09-29 | Millennium Management Llc | 3.28M | 1.56M | 2.84% |
| 2024-09-29 | Vanguard Group Inc | 2.65M | 1.26M | 2.29% |
| 2024-09-29 | Redmile Group, LLC | 1.91M | 904.76K | 1.65% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.77M | 840.15K | 1.53% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 858.61K | 407.15K | 0.74% |
| 2024-08-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 288.70K | 136.90K | 0.25% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 286.41K | 135.82K | 0.25% |
| 2024-09-29 | Variable Insurance Products Fd II-Disciplined Small Cap Portfolio | 179.55K | 85.14K | 0.16% |
| 2024-10-30 | Fidelity Enhanced Small Cap ETF | 120.72K | 57.25K | 0.10% |
Split
| Split | Date |
|---|---|
| 1 : 23 | 2025-01-16 |